ADMA Biologics Inc $ADMA Shares Sold by Perpetual Ltd

Key Points

• Perpetual Ltd has reduced its stake in ADMA Biologics by 18.5%, selling 657,527 shares during the second quarter, now holding 2,894,286 shares valued at about $52.7 million.
• ADMA Biologics reported $0.15 earnings per share, exceeding analysts' expectations; the company's revenue for the quarter was $121.98 million, reflecting a 13.8% increase year-over-year.
• The stock of ADMA Biologics opened at $16.16 and has shown a market capitalization of $3.86 billion, with a PE ratio of 18.79.

Perpetual Ltd lessened its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 18.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,894,286 shares of the biotechnology company's stock after selling 657,527 shares during the period. Perpetual Ltd owned 1.21% of ADMA Biologics worth $52,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in the business. Cetera Investment Advisers boosted its stake in shares of ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after buying an additional 670 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after purchasing an additional 711 shares during the period. GF Fund Management CO. LTD. lifted its position in ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock valued at $120,000 after purchasing an additional 1,089 shares during the period. Journey Strategic Wealth LLC lifted its position in ADMA Biologics by 6.6% in the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock valued at $354,000 after purchasing an additional 1,102 shares during the period. Finally, KBC Group NV lifted its position in ADMA Biologics by 11.5% in the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 1,154 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded up $0.12 during mid-day trading on Monday, reaching $16.03. The stock had a trading volume of 3,179,226 shares, compared to its average volume of 3,166,291. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of 18.64 and a beta of 0.54. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The business has a 50 day simple moving average of $17.22 and a 200 day simple moving average of $18.95.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analysts' expectations of $121.77 million. During the same period last year, the company posted $0.13 earnings per share. The firm's quarterly revenue was up 13.8% compared to the same quarter last year. On average, analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.